Wandercraft is a French robotics firm based in 2012 by Nicolas Simon, Matthieu Masselin, and Jean-Louis Constanza. The founders have been motivated by private experiences, as members of the family suffered from Charcot Marie Tooth, or CMT, illness and confronted restricted mobility choices.
The firm‘s main objective till now has been to allow individuals with extreme gait and mobility impairments to face and stroll once more. Wandercraft developed a product line of dependable, self-balancing exoskeletons able to safely carrying an individual.
Renault to assist develop industrial robotics
This week, Wandercraft unveiled its first humanoid robotic referred to as Calvin. The corporate claimed that it developed the robotic in 40 days, utilizing parts of its exoskeleton merchandise.
The brand new mission comes on the heels of an announcement that Renault Group is making a minority funding in Wandercraft. The automaker is investing together with Wandercraft’s current shareholders and new buyers.
The industrial companions mentioned they intention to make sure the event of Calvin as a household of next-generation robots, primarily for industrial makes use of. Calvin will enable Renault to alleviate its staff from painful and non-ergonomic duties, whereas lowering manufacturing time and thereby growing productiveness.
At a later stage, Renault will assist commercialize the robots and exoskeletons by lowering prices by means of design-to-cost and scaling, two disciplines during which the automotive trade is properly acknowledged. It will assist Wandercraft to place its new exoskeleton Eve in the marketplace and open new enterprise alternatives in robotics.
“Renault Group’s funding marks a defining second for Wandercraft,” mentioned Matthieu Masselin, co-founder and CEO. “This partnership will increase our capacity to construct and scale high-impact, low-cost robotics that enhance the on a regular basis lives of actual individuals—whether or not it’s serving to people with disabilities stroll or supporting industrial staff by means of automation — on the manufacturing facility ground, in clinics and at house. We’re proud to mix our know-how with Renault Group’s industrial excellence to ship the subsequent technology of cell robotics.”
Calvin employs a set of non-grasping palms, and within the video above, the robotic strikes a tote to a shelf. The Robotic Report reached out to the corporate for specs on the robotic, however it didn’t reply as of press time.
The brand new Calvin humanoid robotic is designed for industrial use. Credit score: Wandercraft
Wandercraft exoskeleton in medical trials
Wandercraft’s main product is the Atalante X, a self-stabilizing exoskeleton designed for rehabilitation settings. Launched in 2019, Atalante X permits sufferers to stroll, stand, and relearn pure human movement from their first session. It’s at the moment utilized in almost 100 rehabilitation and medical analysis facilities worldwide.
Key options embody ActiveBalance mode and 12 levels of freedom on the hips, knees, and ankles, enabling a pure gait. The Atalante X gives advantages for each sufferers (early rehabilitation, hands-free strolling, excessive step counts, multi-directional motion) and therapists (fast setup, customizable depth, high-intensity coaching, no want for crutches). Atalante X has acquired FDA clearance for people with spinal wire accidents (T5-L5) and stroke sufferers, and it has a CE mark in Europe for varied circumstances.
The corporate demonstrated the exoskeleton final 12 months when a paraplegic athlete participated in an Olympic flame operating occasion.
Following the success of Atalante X, Wandercraft not too long ago unveiled the Private Exoskeleton, a self-balancing, walk-assist system designed for private, on a regular basis use. The corporate began medical trials of the Private Exoskeleton in February 2025.
This hands-free system goals to offer private freedom of movement in house and group settings. Like Atalante X, it encompasses a absolutely powered hip-knee-ankle decrease physique with 12 actuated levels of freedom and dynamic strolling management.
The Private Exoskeleton, unveiled as a prototype in December 2023, is in its ultimate phases of analysis and growth and can bear medical testing and regulatory overview earlier than changing into broadly obtainable.
Now accepting session submissions!
